Dyne Therapeutics Inc [NASDAQ: DYN] loss -8.82% or 2759990.48 points to close at $2760000.0 with a heavy trading volume of 9320648 shares.
It opened the trading session at $8.73, the shares rose to $9.2 and dropped to $8.41, the range by which the price of stock traded the whole day. The daily chart for DYN points out that the company has recorded -64.53% loss over the past six months.
If we look at the average trading volume of 2.76M shares, DYN reached to a volume of 9320648 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Dyne Therapeutics Inc [DYN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DYN shares is $40.35 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DYN stock is a recommendation set at 1.35. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for Dyne Therapeutics Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on June 24, 2025. While these analysts kept the previous recommendation, Raymond James raised their target price to Outperform. The new note on the price target was released on June 11, 2025, representing the official price target for Dyne Therapeutics Inc stock. Previously, the target price had yet another raise to $34, while Oppenheimer analysts kept a Outperform rating on DYN stock.
The Price to Book ratio for the last quarter was 1.47, with the Price to Cash per share for the same quarter was set at 5.96.
Trading performance analysis for DYN stock
Dyne Therapeutics Inc [DYN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.34. With this latest performance, DYN shares dropped by -27.42% in over the last four-week period, additionally sinking by -64.53% over the last 6 months – not to mention a drop of -63.16% in the past year of trading.
Dyne Therapeutics Inc [DYN]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -59.05%, with Return on Assets sitting at -59.05%.
Dyne Therapeutics Inc [DYN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DYN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Dyne Therapeutics Inc go to 0.26%.
An analysis of Institutional ownership at Dyne Therapeutics Inc [DYN]
There are presently around $110.24%, or 110.86%% of DYN stock, in the hands of institutional investors. The top three institutional holders of DYN stocks are: ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with ownership of 8.02 million shares, which is approximately 8.6697%. FCPM III SERVICES B.V., holding 7.85 million shares of the stock with an approximate value of $$276.86 million in DYN stocks shares; and FCPM III SERVICES B.V., currently with $$260.69 million in DYN stock with ownership which is approximately 7.9853%.
